The PET scan of the Colombian man's brain shows little tau in the entorhinal cortex (blue), a region that normally accumulates the damaging protein early in Alzheimer's disease. (Credit: Mass General Brigham)

May 15, 2023 03:18 PM EDTUpdated May 19, 02:37 PM

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Ryan Cross

Senior Science Correspondent

The man from Colombia was a medical mystery. Thousands of people in the country are born with a devastating mutation that causes Alzheimer’s disease, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Colom­bian man's ge­net­ics should have doomed him to Alzheimer's. In­stead, a rare mu­ta­tion of­fers clue to pro­tec­tion

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Colombian man's genetics should have doomed him to Alzheimer's. Instead, a rare mutation offers clue to protection

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Novartis to cut 139 jobs in NJ as part of commercial refocus

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway